Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

Cigna projected 2025 profit growth of at least 10% on Thursday, after posting quarterly results that beat Wall Street ...

Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, ...

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulation of Humira ...

This current study seeks to identify these policies by comparing the US and EU prosecution histories of formulation patents covering Humira. The USPTO and EPO are counterpart authorities. They each ...

By partnering directly with manufacturers, the insurer aims to dramatically reduce the price of AbbVie's Humira, the world's top-selling drug, by up to 90%. Blue Shield's agreement with drug ...

Cigna surpassed Wall Street estimates for third-quarter profit on Thursday, driven by high demand for biosimilars of a ...

Despite gastroenterologists' tendency to embrace biosimilar treatment options, the use of biosimilar adalimumab versus branded Humira remains comparable across specialties. AbbVie’s Humira ...

Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...

The lower price for members is due to a new Pharmacy Care Reimagined model that unbundles the traditional PBM model, company says. Susan Morse, Executive Editor Improving the Patient Financial ...

So what the heck happened with the blockbuster Humira, in that case? Its patent expired in 2016, but its average list price jumped from $752.41 in 2003 to $2,984.09 in 2021. As Anna Yeo explains ...